<a href=GSK” class=”thirdleft” height=”300″ src=”https://www.pharmaceutical-technology.com/wp-content/uploads/image-digitalinsightresearch/Archive/nri/pharma/GSK_head.jpg” width=”234″ />

GlaxoSmithKline (GSK) has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for Nucala (mepolizumab) to treat bronchial asthma patients in the country.

The move follows the approval of Nucala in the US, which was a world first for an anti-interleukin-5 (IL-5) treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nucala is a monoclonal antibody that stops IL-5 from binding to its receptor on the surface of eosinophils. The inhibition of IL-5 binding reduces blood, tissue and sputum eosinophil levels.

This medicine is administered as a 100mg fixed dose subcutaneous injection, once every four weeks, to treat bronchial asthma in patients with refractory asthma, in addition to their existing respiratory medication.

Nucala will now be made available for adults and adolescents aged 12 years or more in Japan.

GSK Japan president Philippe Fauchet said: "Approval of Nucala not only complements our respiratory portfolio but also gives us the opportunity to make a difference to the lives of more patients in Japan.

"Approval of Nucala not only complements our respiratory portfolio but also gives us the opportunity to make a difference to the lives of more patients in Japan."

"It is our aim to make Nucala available in Japan as soon as possible to support the needs of a significant group of severe asthma patients whose condition is driven by eosinophilic inflammation, which is difficult to control."

The approval from MHLW is based on data from the global clinical development programme, including the pivotal DREAM (MEA112997), MENSA (MEA115588) and SIRIUS (MEA115575) studies which showed efficacy and safety of mepolizumab in patients with severe eosinophilic asthma.

In the phase III MENSA and SIRIUS studies, patients had peripheral blood eosinophil levels greater than or equal to 150 cells/µL at initiation of treatment or greater than or equal to 300 cells/µL within the past 12 months.


Image: GlaxoSmithKline head office in London, UK. Photo: courtesy of Ian Wilson via Wikipedia.